深部脑部刺激设备市场 - 全球产业规模、份额、趋势、机会及预测（按产品类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球深部脑部刺激市场预计将从 2025 年的 15.6 亿美元成长到 2031 年的 27.7 亿美元，复合年增长率达到 10.04%。

这些植入式系统透过向特定脑区传递电脉衝来调节神经活动并控制神经系统疾病。市场成长主要受帕金森氏症和癫痫等疾病日益普遍以及全球人口老化（老年人更容易患神经退化性疾病）的推动。此外，患者对先进神经系统治疗的认知不断提高也促进了全球此类系统的普及。世界卫生组织（世卫组织）报告称，到2024年，全球约有5,000万人将受到癫痫的影响，凸显了有效治疗方法的紧迫性。

然而，高昂的设备成本和复杂的法规环境构成了市场扩张的重大障碍。植入和后续维护带来的沉重经济负担限制了设备的普及，尤其是在医疗预算有限的开发中国家。此外，手术的潜在风险以及设备编程所需的技术复杂性也令患者和医疗服务提供者望而却步，阻碍了市场渗透。

市场驱动因素

包括帕金森氏症在内的神经退化性疾病盛行率不断上升，是推动脑部深部刺激（DBS）市场成长的主要因素，也因此迫切需要可扩展的慢性运动功能管理治疗方法。全球人口老化加剧了复杂神经系统疾病的发生率，促使人们寻求比单纯药物治疗效果更好的长期治疗方案。这项负担十分沉重；根据世界卫生组织（WHO）2024年3月发布的《世界神经病学现况报告》，目前全球有超过30亿人患有神经系统疾病，这是导致残疾和疾病的主要原因之一。不断扩大的患者群体凸显了植入式神经调控设备的临床紧迫性，尤其是在传统药物疗法无法提供充分缓解或引起严重副作用的情况下。

同时，DBS设备小型化和电池续航时间延长的技术创新正在革新该领域，突破了传统设备尺寸和维护的限制。製造商正优先研发更小巧、可充电的植入式脉衝产生器（IPG），以提高病患舒适度并延长使用寿命。例如，雅培公司在2024年1月发布的新闻稿中宣布其Liberta RC™ DBS系统获得FDA核准，并指出该新型设备配备的电池在典型充电后可续航37天，显着减少了患者频繁操作设备的需要。这些技术进步正在转化为行业领先企业的财务成功。 2024年5月，Medtronic报告称，其脑调控部门实现了两位数的低段有机收入成长，这反映了这些现代化刺激技术在全球范围内的广泛应用。

市场挑战

高昂的设备成本和复杂的法规结构是全球深部脑部刺激市场成长的主要障碍。手术、设备本身以及必要的术后程序设定都需要大量的资金投入，这给患者和医疗服务提供者都设置了很高的进入门槛。在许多医疗体系中，严格的报销政策和预算限制迫使医生在考虑深部脑部刺激之前必须尝试所有其他治疗方法，从而延迟或阻碍了该疗法的普及。这种经济上的阻碍限制了市场规模，并使很大一部分患者，特别是那些自付费用高昂的发展中地区患者，难以负担这项疗法。

神经退化性疾病的治疗带来了巨大的经济负担，凸显了这项经济挑战的严峻。加拿大帕金森氏症协会估计，到2024年，帕金森氏症造成的经济负担总额将达到33亿加元，其中约90%的负担由患者及其家庭承担。这种沉重的个人负担直接阻碍了诸如脑深部刺激（DBS）等昂贵医疗技术的普及，限制了市场渗透率，并降低了整个行业的收入。

市场趋势

深部脑部刺激疗法的应用范围已显着扩展，涵盖神经精神和认知障碍，使其适用于帕金森氏症等传统运动障碍以外的更多患者群体。业内相关人员正加大对临床试验的投入，以检验神经调控疗法对复杂精神疾病（例如药物治疗无效的难治性忧郁症(TRD)）的疗效。这一趋势标誌着治疗策略从控制运动症状转向调节情绪和认知迴路。例如，根据雅培公司2024年9月发布的新闻稿，该公司已启动一项关键的TRANSCEND研究，该研究招募了100名受试者，旨在评估深部脑部刺激疗法治疗难治性忧郁症患者的安全性和有效性。

同时，远端患者管理和远端程式设计平台的整合正成为克服地域障碍、提高术后护理效率的关键趋势。新型数位生态系统使临床医生能够远端调整刺激参数并监测患者病情，从而显着减轻了以往需要频繁前往诊所进行微调的患者的负担。这种能力对于扩大治疗覆盖范围，惠及专科医师稀缺的欠发达地区至关重要。正如雅培公司在2024年1月发布的关于其Liberta RC™ DBS系统的新闻稿中所指出的，内部研究表明，市场对互联医疗解决方案有着巨大的需求，因为美国DBS患者平均需要奔波150英里以上才能见到运动障碍专科医生。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球深部脑部刺激设备市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（双通道深部脑部刺激器、单通道深部脑部刺激器）
  • 依类型（可充电式、不可充电式）
  • 因使用（帕金森氏症、癫痫、自发性震颤、肌肌张力不全症失调、强迫症）
  • 依最终使用者（医院、门诊手术中心、神经科科诊所等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美深部脑部刺激市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲深部脑部刺激市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区深部脑部刺激设备市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲深部脑部刺激设备市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲深部脑刺激市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球深部脑部刺激设备市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Aleva Neurotherapeutics SA
• NeuroPace, Inc.
• Beijing PINS Medical Co., Ltd.
• SceneRay Corporation Ltd.
• Renishaw plc
• LivaNova plc
• Functional Neuromodulation Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Deep Brain Stimulation Devices Market is projected to expand from USD 1.56 Billion in 2025 to USD 2.77 Billion by 2031, achieving a compound annual growth rate of 10.04%. These implantable systems function by transmitting electrical impulses to specific brain regions to regulate neural activity and manage neurological disorders. The market's growth is largely fueled by the increasing prevalence of conditions such as Parkinson's disease and epilepsy, coupled with an aging global population susceptible to neurodegenerative ailments. Additionally, growing patient awareness regarding advanced neurological treatments supports higher adoption rates worldwide. Highlighting the urgent need for effective therapeutic solutions, the World Health Organization reported in 2024 that epilepsy affects approximately 50 million people globally.

Conversely, high equipment costs and intricate regulatory environments pose significant barriers to market expansion. The substantial financial load associated with implantation and ongoing maintenance restricts accessibility, particularly in developing economies facing healthcare budget constraints. Furthermore, potential surgical risks and the technical complexity involved in device programming can discourage both patients and healthcare providers, thereby hindering broader market penetration.

Market Driver

The rising incidence of Parkinson's disease and other neurodegenerative conditions acts as a primary catalyst for the growth of the Deep Brain Stimulation (DBS) market, creating a critical need for scalable interventions in chronic movement management. As global demographics shift towards an older population, the frequency of complex neurological disorders is increasing, driving demand for long-term therapeutic solutions that offer better results than medication alone. This burden is significant; the World Health Organization's March 2024 'Global Status Report on Neurology' states that neurological conditions now impact over 3 billion individuals worldwide, ranking as the leading cause of disability and ill health. This expanding patient pool underscores the clinical urgency for implantable neuromodulation devices, especially when traditional pharmacological treatments fail to provide adequate relief or cause severe side effects.

Simultaneously, technological innovations in DBS device miniaturization and battery longevity are revolutionizing the sector by overcoming historical limitations related to device size and maintenance. Manufacturers are prioritizing the creation of smaller, rechargeable implantable pulse generators (IPGs) that enhance patient comfort and extend operational life. For example, according to Abbott's January 2024 press release regarding the FDA approval of the Liberta RC(TM) DBS System, the new device features a battery capable of lasting 37 days between charges under normal settings, drastically reducing the need for frequent patient interaction. These engineering advancements are translating into financial success for industry leaders; Medtronic reported in May 2024 that its Brain Modulation division achieved low-double digit organic revenue growth, reflecting strong global adoption of these modernized stimulation technologies.

Market Challenge

High device costs and complex regulatory frameworks constitute a major obstacle to the growth of the Global Deep Brain Stimulation Devices Market. The significant capital required for the surgical procedure, the device itself, and necessary post-operative programming establishes a high barrier to entry for both patients and healthcare providers. In many healthcare systems, strict reimbursement policies and budget limitations force physicians to exhaust all pharmacological options before considering DBS, thereby delaying or preventing the adoption of this therapy. This economic friction restricts the market size, as the therapy remains financially out of reach for a vast segment of the patient population, particularly in developing regions where out-of-pocket expenses are prohibitive.

The magnitude of this financial challenge is highlighted by the immense economic pressure placed on those managing neurodegenerative conditions. According to Parkinson Canada in 2024, the total economic burden of Parkinson's disease is estimated at $3.3 billion, with patients and their families bearing nearly 90% of these costs. This heavy personal financial liability directly discourages the uptake of expensive medical technologies like DBS, reducing widespread market penetration and dampening overall industry revenue.

Market Trends

The scope of Deep Brain Stimulation is significantly widening to include neuropsychiatric and cognitive disorders, extending the addressable patient population beyond traditional movement disorders like Parkinson's disease. Industry participants are increasingly investing in clinical trials to validate neuromodulation for complex psychiatric conditions, such as Treatment-Resistant Depression (TRD), where pharmacological interventions often fail. This trend marks a pivotal transition from managing motor symptoms to modifying mood and cognitive circuits. For instance, according to an Abbott press release in September 2024, the company initiated the pivotal TRANSCEND study to enroll 100 participants to evaluate the safety and effectiveness of DBS therapy for patients suffering from treatment-resistant depression.

Concurrently, the integration of remote patient management and tele-programming platforms is emerging as a critical trend to overcome geographical barriers and improve postoperative care efficiency. New digital ecosystems allow clinicians to adjust stimulation parameters and monitor patient diagnostics virtually, significantly reducing the logistical burden on patients who previously required frequent in-clinic visits for fine-tuning. This capability is essential for expanding therapy access to underserved regions where specialists are scarce. As noted in Abbott's January 2024 press release for the Liberta RC(TM) DBS System, internal research indicated that the average DBS user in the United States must travel more than 150 miles to access a movement disorder specialist, underscoring the vital market need for connected care solutions.

Key Market Players

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Aleva Neurotherapeutics SA
• NeuroPace, Inc.
• Beijing PINS Medical Co., Ltd.
• SceneRay Corporation Ltd.
• Renishaw plc
• LivaNova plc
• Functional Neuromodulation Ltd.

Report Scope

In this report, the Global Deep Brain Stimulation Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Deep Brain Stimulation Devices Market, By Product Type

• Dual-channel Deep Brain Stimulator
• Single-channel Deep Brain Stimulator

Deep Brain Stimulation Devices Market, By Type

• Rechargeable
• Non-Rechargeable

Deep Brain Stimulation Devices Market, By Application

• Parkinson's Disease
• Epilepsy
• Essential Tremor
• Dystonia
• Obsessive Compulsive Disorder

Deep Brain Stimulation Devices Market, By End User

• Hospitals
• Ambulatory Surgical Centers
• Neurological Clinics
• Others

Deep Brain Stimulation Devices Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Deep Brain Stimulation Devices Market.

Available Customizations:

Global Deep Brain Stimulation Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Deep Brain Stimulation Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Dual-channel Deep Brain Stimulator, Single-channel Deep Brain Stimulator)
  • 5.2.2. By Type (Rechargeable, Non-Rechargeable)
  • 5.2.3. By Application (Parkinson's Disease, Epilepsy, Essential Tremor, Dystonia, Obsessive Compulsive Disorder)
  • 5.2.4. By End User (Hospitals, Ambulatory Surgical Centers, Neurological Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Deep Brain Stimulation Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Deep Brain Stimulation Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Deep Brain Stimulation Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Deep Brain Stimulation Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Deep Brain Stimulation Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Deep Brain Stimulation Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Deep Brain Stimulation Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Deep Brain Stimulation Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Deep Brain Stimulation Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Deep Brain Stimulation Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Deep Brain Stimulation Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Deep Brain Stimulation Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Deep Brain Stimulation Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Deep Brain Stimulation Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Deep Brain Stimulation Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Deep Brain Stimulation Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Deep Brain Stimulation Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Deep Brain Stimulation Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Deep Brain Stimulation Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Deep Brain Stimulation Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Deep Brain Stimulation Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Deep Brain Stimulation Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Deep Brain Stimulation Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Deep Brain Stimulation Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Deep Brain Stimulation Devices Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boston Scientific Corporation
• 15.3. Abbott Laboratories
• 15.4. Aleva Neurotherapeutics SA
• 15.5. NeuroPace, Inc.
• 15.6. Beijing PINS Medical Co., Ltd.
• 15.7. SceneRay Corporation Ltd.
• 15.8. Renishaw plc
• 15.9. LivaNova plc
• 15.10. Functional Neuromodulation Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer